BLOGS WEBSITE

JDRF: Request for Applications – Beta Cell Regeneration and Survival Innovative Grants

JDRF provides seed funding for highly innovative research with significant potential to accelerate the mission of JDRF. Proposals should address key outstanding questions and have the potential to lead to a change in the current paradigm or conventional wisdom and/or lead to a groundbreaking discovery. Preliminary data is not required in the proposal but the underlying premise, goal, or hypothesis must be plausible and testable and the proposal must be focused with a well-defined goal that is achievable within the timeframe of the award.

Please refer to the JDRF’s Beta Cell Regeneration and Survival research priority areas for further details.

Funding & Duration

Innovative grants provide one year of support for a maximum of USD $100,000 (approx. AUD $136,000) in direct costs, plus indirect costs of 10%.

Eligibility

Proposals may be submitted by domestic and foreign non-profit organisations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.

Innovative (but not pilot and research tool) proposals from for-profit organizations will also be considered.

Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility.

To assure continued excellence and diversity among applicants and awardees, JDRF welcomes proposals from all qualified individuals and encourages proposals from persons with disabilities, women, and members of minority groups underrepresented in the sciences.

There are no citizenship requirements for this program.

Submission Requirements & Due Date

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding, Sciences. Bookmark the permalink.
 

Comments are closed.